Today: 20 June 2026
Browse Category

NASDAQ:RPLM 29 May 2026

Replimune jumps 85% after FDA opens up third dose for skin cancer therapy

Replimune jumps 85% after FDA opens up third dose for skin cancer therapy

Replimune Group shares soared 85% to $8.64 Friday after the company said it will resubmit its advanced melanoma drug RP1 to the FDA, which agreed to a priority review. The FDA had rejected the therapy in April, citing lack of a control group. Replimune plans to file again within days and will present new trial data at an oncology meeting May 30. Bristol Myers fell 0.6%, while Iovance dropped 6.5%.
29 May 2026
··

Stock Market Today

  • Parabilis Medicines Director Buys $474,000 Shares Post-IPO, Signaling Confidence in PBLS Stock
    June 20, 2026, 1:37 PM EDT. Parabilis Medicines (NASDAQ:PBLS) director Alan Sebulsky purchased 17,500 shares for approximately $474,000 shortly after the company's IPO. The purchase, made through his investment vehicle Apothecary Capital LLC, raised his indirect holdings to 30,000 shares. The transaction price of $27.06 per share exceeded the June 15 closing price by about 8.2%, indicating strong confidence. Parabilis focuses on developing cell-penetrating miniproteins targeting cancer cells and has a $3.29 billion market cap. Sebulsky, noted for board roles at Jazz Pharmaceuticals and Arrow International, increasing his stake could be seen as a bullish indicator for investors assessing PBLS.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq gets boost from AI chip stocks; Fed rate question stays in focus

20 June 2026
Intel soared 10.6% after President Trump announced Apple will partner with the company on U.S. chip design and manufacturing, fueling a semiconductor-led rally that lifted the S&P 500 by 0.93% and the Nasdaq by 2.43% in a holiday-shortened week, even as investors remain wary of persistent inflation and potential Fed rate hikes.
Go toTop